{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:31:36Z","timestamp":1793604696749,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.contraception.2022.10.004","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T11:00:12Z","timestamp":1666004412000},"page":"44-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Tolerability and safety of the estetrol\/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials"],"prefix":"10.1016","volume":"116","author":[{"given":"Melissa J.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Kaunitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Achilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Zatik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Weyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terhi","family":"Piltonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Suturina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Apolikhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Foidart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Creinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2022.10.004_bib0001","unstructured":"United Nations. Contraceptive use by method. 2019. Available at: https:\/\/digitallibrary.un.org\/record\/3849735?ln=en (accessed June 27, 2022)."},{"key":"10.1016\/j.contraception.2022.10.004_bib0002","first-page":"83","article-title":"Use of contraception among reproductive-aged women in the United States, 2014 and 2016","volume":"1","author":"Kavanaugh","year":"2020","journal-title":"F S Rep"},{"key":"10.1016\/j.contraception.2022.10.004_bib0003","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.contraception.2011.02.013","article-title":"Current issues and available options in combined hormonal contraception","volume":"84","author":"Bitzer","year":"2011","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.10.004_bib0004","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.jsxm.2019.08.005","article-title":"Hormonal Contraception and Female Sexuality: Position Statements from the European Society of Sexual Medicine (ESSM)","volume":"16","author":"Both","year":"2019","journal-title":"J Sex Med"},{"key":"10.1016\/j.contraception.2022.10.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmjsrh-2020-200658","article-title":"Towards individualized contraceptive counselling: clinical and reproductive factors associated with self-reported hormonal contraceptive-induced adverse mood symptoms","author":"Lundin","year":"2021","journal-title":"BMJ Sex Reprod Health"},{"key":"10.1016\/j.contraception.2022.10.004_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004861.pub2","article-title":"Types of progestogens in combined oral contraception: effectiveness and side-effects","author":"Lawrie","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2022.10.004_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003987.pub5","article-title":"Combination contraceptives: effects on weight","author":"Gallo","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2022.10.004_bib0008","first-page":"43","article-title":"Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates","volume":"7","author":"Villavicencio","year":"2016","journal-title":"Open Access J Contracept"},{"key":"10.1016\/j.contraception.2022.10.004_bib0009","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ijgo.12455","article-title":"A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception","volume":"141","author":"Dragoman","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.contraception.2022.10.004_bib0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.thromres.2018.03.005","article-title":"Systematic review and meta-analysis of the association of combined oral contraceptives on the risk of venous thromboembolism: The role of the progestogen type and estrogen dose","volume":"165","author":"Oedingen","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.contraception.2022.10.004_bib0011","doi-asserted-by":"crossref","first-page":"h2135","DOI":"10.1136\/bmj.h2135","article-title":"Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"350","author":"Vinogradova","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2022.10.004_bib0012","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/jmwh.12992","article-title":"Women's Contraceptive Perceptions, Beliefs, and Attitudes: An Integrative Review of Qualitative Research","volume":"65","author":"Alspaugh","year":"2020","journal-title":"J Midwifery & Women's Health"},{"key":"10.1016\/j.contraception.2022.10.004_bib0013","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.contraception.2009.09.009","article-title":"Perceptions of the safety of oral contraceptives among a predominantly Latina population in Texas","volume":"81","author":"Grossman","year":"2010","journal-title":"Contraception"},{"issue":"376","key":"10.1016\/j.contraception.2022.10.004_bib0014","first-page":"e1","article-title":"Predictors of contraceptive switching and discontinuation within the first 6 months of use among Highly Effective Reversible Contraceptive Initiative Salt Lake study participants","volume":"220","author":"Simmons","year":"2019","journal-title":"Am J Obstet Gynecol"},{"issue":"412","key":"10.1016\/j.contraception.2022.10.004_bib0015","first-page":"e1","article-title":"Oral contraceptive discontinuation: do side effects matter?","volume":"196","author":"Westhoff","year":"2007","journal-title":"Am J Obstetrics and Gynecol"},{"key":"10.1016\/j.contraception.2022.10.004_bib0016","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.15252\/emmm.201404112","article-title":"The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor alpha modulation, uncoupling nuclear and membrane activation","volume":"6","author":"Abot","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.contraception.2022.10.004_bib0017","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1152\/physrev.00024.2016","article-title":"Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications","volume":"97","author":"Arnal","year":"2017","journal-title":"Physiol Rev"},{"key":"10.1016\/j.contraception.2022.10.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1210\/js.2019-SUN-LB001","article-title":"Estetrol (E4) Is a Unique Estrogen with Selective Actions in Tissues Which Are Distinctly Different from the Actions of SERMs","volume":"3","author":"Foidart","year":"2019","journal-title":"J Endocrine Soc"},{"key":"10.1016\/j.contraception.2022.10.004_bib0019","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008950","article-title":"Predominant role of nuclear versus membrane estrogen receptor alpha in arterial protection: implications for estrogen receptor alpha modulation in cardiovascular prevention\/safety","volume":"7","author":"Guivarc'h","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.contraception.2022.10.004_bib0020","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.contraception.2020.08.015","article-title":"Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters","volume":"102","author":"Douxfils","year":"2020","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.10.004_bib0021","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1530\/JOE-14-0549","article-title":"Estetrol is a weak estrogen antagonizing estradiol-dependent mammary gland proliferation","volume":"224","author":"G\u00e9rard","year":"2015","journal-title":"J Endocrinol"},{"key":"10.1016\/j.contraception.2022.10.004_bib0022","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.contraception.2021.01.001","article-title":"Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone","volume":"103","author":"Klipping","year":"2021","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.10.004_bib0023","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.contraception.2016.08.018","article-title":"Reduced haemostatic effects with drospirenone-based oral contraceptives containing estetrol versus ethinyl estradiol","volume":"95","author":"Kluft","year":"2017","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.10.004_bib0024","first-page":"463","article-title":"Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives","volume":"20","author":"Mawet","year":"2015","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2022.10.004_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2021.05.002","article-title":"Estetrol-Drospirenone Combination Oral Contraceptive: North American Phase 3 Efficacy and Safety Results","author":"Creinin","year":"2021","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.10.004_bib0026","article-title":"Estetrol-Drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern, and safety in Europe and Russia","author":"Gemzell-Danielsson","year":"2021","journal-title":"BJOG"},{"key":"10.1016\/j.contraception.2022.10.004_bib0027","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/GRF.0b013e318159bf8a","article-title":"Study design to evaluate the safety and effectiveness of hormonal contraception for women","volume":"50","author":"Kapp","year":"2007","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.contraception.2022.10.004_bib0028","first-page":"1499","article-title":"Managing adverse effects of hormonal contraceptives","volume":"82","author":"Grossman Barr","year":"2010","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.contraception.2022.10.004_bib0029","doi-asserted-by":"crossref","first-page":"d6423","DOI":"10.1136\/bmj.d6423","article-title":"Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9","volume":"343","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2022.10.004_bib0030","doi-asserted-by":"crossref","first-page":"32836","DOI":"10.1016\/j.contraception.2006.12.018","article-title":"Range of published estimates of venous thromboembolism incidence in young women","volume":"75","author":"Heinemann","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.10.004_bib0031","unstructured":"European Medicines Agency. Drovelis (estetrol \/drospirenone): EPAR - public assessment report. 2021. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/drovelis-epar-public-assessment-report_en.pdf (accessed June 27, 2022)"},{"key":"10.1016\/j.contraception.2022.10.004_bib0032","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0010-7824(97)00119-4","article-title":"First-time use of newer oral contraceptives and the risk of venous thromboembolism","volume":"56","author":"Suissa","year":"1997","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.10.004_bib0033","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1001\/archinte.164.18.1965","article-title":"Risk of Venous Thromboembolic Disease Associated With Hormonal Contraceptives and Hormone Replacement Therapy: A Clinical Review","volume":"164","author":"Gomes","year":"2004","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.contraception.2022.10.004_bib0034","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ogc.2015.07.007","article-title":"Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?","volume":"42","author":"Han","year":"2015","journal-title":"Obstet Gynecol Clin North Am"},{"key":"10.1016\/j.contraception.2022.10.004_bib0035","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/humrep\/15.4.817","article-title":"Recurrent use of newer oral contraceptives and the risk of venous thromboembolism","volume":"15","author":"Suissa","year":"2000","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2022.10.004_bib0036","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.contraception.2014.01.013","article-title":"Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel\/ethinyl estradiol combined oral contraceptive","volume":"89","author":"Portman","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.10.004_bib0037","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.contraception.2015.10.007","article-title":"Efficacy and safety of a 21\/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol","volume":"93","author":"Kroll","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.10.004_bib0038","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/GME.0000000000000823","article-title":"Pharmacodynamic effects of the fetal estrogen estetrol in postmenopausal women: results from a multiple-rising-dose study","volume":"24","author":"Coelingh Bennink","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.contraception.2022.10.004_bib0039","unstructured":"NEXTSTELLIS. Prescibing Information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214154s000lbl.pdf (accessed June 27, 2022)."},{"key":"10.1016\/j.contraception.2022.10.004_bib0040","unstructured":"Drovelis (estetrol \/drospirenone). Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/drovelis (accessed June 27, 2022)."}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001078242200395X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001078242200395X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:22:27Z","timestamp":1757881347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001078242200395X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":40,"alternative-id":["S001078242200395X"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2022.10.004","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerability and safety of the estetrol\/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2022.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}